The Roadmap Series

The HIV Drug Pipeline and its Patents: August 2013

In August 2013, the Initiative for Medicines, Access & Knowledge (I-MAK) created The Roadmap: The HIV Drug Pipeline and its Patents, the first report to showcase clinical, cost, and legal/patent information on important HIV antiretroviral (ARV) medicines in the pipeline. It aimed to help expand access to the next generation of lifesaving ARVs in multiple ways. Using The Roadmap, advocates can decide which medicines need short- or long-term attention and make informed decisions about the best strategies to pursue, such as patent oppositions, compulsory licenses (CL), voluntary license (VL) negotiations, and/or direct advocacy.

The Roadmap Special Edition Report on Dolutegravir: June 2017

This report expands on the information provided in the original Roadmap to equip stakeholders with current clinical, cost, and patent information to inform decision-making about the best strategies to expand currently limited access to DTG, a second-generation, best in class HIV integrase strand transfer inhibitor that greatly improves upon drugs in its class and is highly suitable for large treatment programs in low- and middle-income countries.

The Roadmap Special Edition Report on Tenofovir Alafenamide Fumarate: April 2018

This report expands on the information provided in the original Roadmap, and most importantly, aims to provide the international community with critical analysis well in advance of when policy-makers will have to determine how TAF may be used in HIV treatment programs.